RCEL Stock Risk & Deep Value Analysis
AVITA Medical Inc
DVR Score
out of 10
What You Need to Know About RCEL Stock
We analyzed AVITA Medical Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RCEL through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
RCEL Risk Analysis & Red Flags
What Could Go Wrong
The company is currently unprofitable and if vitiligo adoption rates are slower than anticipated, the need for funding from the $200M shelf registration could lead to substantial share dilution, significantly impacting shareholder returns and pushing profitability further out.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
Low
Red Flags
- ⚠
Potential significant share dilution (S-3 filing for up to $200M in equity offerings relative to $0.09B market cap)
- ⚠
Continued unprofitability (negative EPS estimates for next quarter)
- ⚠
Lack of granular balance sheet and cash flow data available in public search results
Upcoming Risk Events
- 📅
Slower-than-expected vitiligo market adoption
- 📅
Actual issuance of shares from $200M S-3 shelf registration causing significant dilution
When to Reconsider
- 🚪
Quarterly vitiligo revenue growth decelerates or misses expectations significantly
- 🚪
Announcement of a major dilutive capital raise from the S-3 shelf registration without commensurate growth outlook
- 🚪
Sustained breach of critical technical support levels (e.g., below $3.00)
Unlock RCEL Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
AVITA Medical is an aggressive growth investment focused on the significant upside from its RECELL System's commercialization in the vast vitiligo market. Despite current unprofitability and the financial risk associated with potential share dilution from its $200M S-3 shelf registration, the company's proprietary technology, regulatory moats, and early revenue acceleration position it for substantial market share capture and potential 10x growth within 3-5 years if execution on vitiligo adoption is robust.
Is RCEL Stock Undervalued?
Unlock the full AI analysis for RCEL
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
RCEL Price Targets & Strategy
12-Month Target
$8.25
Bull Case
$12.50
Bear Case
$2.00
Valuation Basis
Based on 2.5x forward P/S applied to projected $80M FY26 revenue.
Entry Strategy
Consider dollar-cost averaging between $3.50 and $4.00, leveraging recent price weakness to build a position in anticipation of strong vitiligo commercialization data.
Exit Strategy
Take initial profits at $8.00-$10.00 if commercialization targets are met. Set a stop-loss order if the price drops below $3.00, indicating a breakdown in the growth thesis or unexpected dilution.
Portfolio Allocation
5% for aggressive risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is RCEL Financially Healthy?
Valuation
P/E Ratio
-2.18
Forward P/E
-18.43
Price/Sales
1.55
Balance Sheet
Current Ratio
0.57
Quick Ratio
0.46
Debt/Equity
-2.77
Cash Flow
EBITDA
-$40.24M
Does RCEL Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
RECELL's unique technology and established regulatory pathway provide a defensible position. However, continued R&D and market leadership are crucial as competitive or generic alternatives could emerge over the long term, potentially eroding the advantage.
Moat Erosion Risks
- •Emergence of superior or more cost-effective competing regenerative medicine therapies
- •Patent expiry or successful legal challenges to IP
- •Slower-than-expected physician adoption hindering network effects
RCEL Competitive Moat Analysis
Sign up to see competitive advantages
RCEL Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (no specific data available, general retail sentiment not captured)
Institutional Sentiment
Neutral (no analyst consensus, upgrades/downgrades available)
Insider Activity (Form 4)
CFO David D. O'Toole bought 1,800 shares at $4.78. Mathewes Daniel Jason sold 811 shares on 2026-04-01. Tonkin Dusty sold 1,929 shares on 2026-04-01.
Options Flow
Normal options activity (no specific unusual activity provided)
Earnings Intelligence
Next Earnings
Estimated early-May 2026 (for Q1 2026)
Surprise Probability
Medium (given limited historical data and analyst coverage provided)
Historical Earnings Pattern
Not provided in real-time intelligence for specific historical earnings reaction patterns.
Key Metrics to Watch
Competitive Position
Top Competitor
No specific competitor ticker provided in research.
Market Share Trend
Gaining ground in the vitiligo segment due to recent FDA approval for RECELL System.
Valuation vs Peers
Cannot be determined without peer valuation data or RCEL's specific valuation ratios.
Competitive Advantages
- •Proprietary RECELL System technology
- •FDA approvals for multiple indications (burns, vitiligo)
- •Demonstrated clinical efficacy in wound care and repigmentation
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive RCEL Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings report (likely in early-May 2026)
- •Continued positive data and adoption rates for RECELL in vitiligo
Medium-Term (6-18 months)
- •Expanded reimbursement coverage for vitiligo indication
- •Potential for additional RECELL indications or market expansion
Long-Term (18+ months)
- •Establishment as a market leader in regenerative dermatology
- •Achieving sustained profitability and positive free cash flow
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for RCEL?
- ✓
Acceleration in quarter-over-quarter vitiligo revenue growth
- ✓
Progress towards positive operating cash flow and reduced net losses
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How AVITA Medical Inc Makes Money
AVITA Medical develops and commercializes the RECELL System, an innovative medical device that allows healthcare professionals to prepare a patient's own skin cells (autologous spray-on skin) at the point of care. This technology is used for treating severe burns, and more recently, for repigmenting stable vitiligo lesions. The company generates revenue by selling these single-use RECELL System devices directly to hospitals, burn centers, and dermatology clinics, enabling them to provide advanced regenerative medicine solutions.
Read Full Business Model BreakdownFAQ
What is the DVR Score for AVITA Medical Inc (RCEL)?
As of April 6, 2026, AVITA Medical Inc has a DVR Score of 7.5 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of AVITA Medical Inc?
AVITA Medical Inc's market capitalization is approximately $121.1M..
What is the risk level for RCEL stock?
Our analysis rates AVITA Medical Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of RCEL?
AVITA Medical Inc currently has a price-to-earnings (P/E) ratio of -2.2. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is AVITA Medical Inc's revenue growing?
AVITA Medical Inc has reported revenue growth of -4.3%. Revenue has been declining, which warrants closer examination.
Is RCEL stock profitable?
AVITA Medical Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the RCEL DVR analysis updated?
Our AI-powered analysis of AVITA Medical Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 6, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for RCEL (AVITA Medical Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.